Lv7
4880 积分 2021-02-21 加入
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
1个月前
已关闭
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
1个月前
已关闭
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
1个月前
已完结
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
2个月前
已完结
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
4个月前
已完结
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
5个月前
已完结
Regulators of CD8+ T cell exhaustion
5个月前
已完结
Exploring the next generation of antibody–drug conjugates
7个月前
已完结
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
8个月前
已完结
Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients
8个月前
已完结
皖公网安备34019202002308